Is ERα a Tamoxifen Predictive Factor in ERα Negative Breast Cancer in Premenopausal Women?

被引：0
|
作者：
Kallstrom, A-C
Ferno, M.
Jonsson, P. E.
Landberg, G.
Nordenskjold, B.
Stal, O.
机构：
[1] Helsingborgs Lasarett, Helsingborg, Sweden
[2] Linkoping Univ, S-58183 Linkoping, Sweden
[3] Lund Univ, S-22100 Lund, Sweden
[4] Lund Univ, Malmo, Sweden
[5] Lund Univ, Malmo Univ Hosp, Malmo, Sweden
[6] Univ Manchester, Manchester M13 9PL, Lancs, England
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-PD05-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD05-06
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?
    Raina, Vinod
    NATURE CLINICAL PRACTICE ONCOLOGY, 2004, 1 (01): : 20 - 21
  • [42] Estrogen Receptor Alpha Negative (ER-) Breast Cancer Stem Cells in ER plus Cell Lines and Primary Cancers Are Enriched by Tamoxifen Therapy
    O'Brien, C. S.
    Howell, S. J.
    Gandhi, A.
    Gee, J.
    Lykkesfeldt, A.
    Nicholson, R. I.
    Clarke, R. B.
    CANCER RESEARCH, 2010, 70
  • [43] A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer
    Lu Cao
    Guomin Xiang
    Fang Liu
    Cong Xu
    Jing Liu
    Qingxiang Meng
    Shuhua Lyu
    Shuling Wang
    Yun Niu
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 609 - 620
  • [44] A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer
    Cao, Lu
    Xiang, Guomin
    Liu, Fang
    Xu, Cong
    Liu, Jing
    Meng, Qingxiang
    Lyu, Shuhua
    Wang, Shuling
    Niu, Yun
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (03) : 609 - 620
  • [45] Nuclear factor I/B regulates cell proliferation of ER negative breast cancer
    Kim, Jeong-Ah
    Han, Wonshik
    Jung, Eun-Mi
    Hwang, Ki-Tae
    Noh, Dong-Young
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [46] Tamoxifen Resistance in Estrogen Receptor Positive (ER plus ) Breast Cancer Is Driven by Estrogen Receptor Negative (ER-) Cancer Stem-Like Cells.
    O'Brien, C. S.
    Howell, S. J.
    Gee, J.
    Lykkesfeldt, A. E.
    Nicholson, R., I
    Clarke, R. B.
    CANCER RESEARCH, 2009, 69 (24) : 807S - 807S
  • [47] ERα and ERαΔ5 expression in tamoxifen-treated breast tumours.
    Girdler, F
    Clayton, SJ
    Walker, J
    Fox, JC
    Brotherick, I
    Browell, DA
    Cunliffe, WJ
    Higgs, MJ
    Hemming, D
    Lennard, TWJ
    Young, JR
    Shenton, BK
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 293 - 293
  • [48] Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub-phenotype ex vivo
    K. Pather
    T. N. Augustine
    Scientific Reports, 10
  • [49] Estrogen receptor β (ERβ) level but not its ERβcx variant helps to predict tamoxifen resistance in breast cancer
    Esslimani-Sahla, M
    Simony-Lafontaine, J
    Kramar, A
    Lavaill, R
    Mollevi, C
    Warner, M
    Gustallsson, JÅ
    Rochefort, H
    CLINICAL CANCER RESEARCH, 2004, 10 (17) : 5769 - 5776
  • [50] Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub-phenotype ex vivo
    Pather, K.
    Augustine, T. N.
    SCIENTIFIC REPORTS, 2020, 10 (01)
12345